Évaluation des pratiques de prescription des facteurs de croissance granulocytaires en oncologie au Maroc (notice n° 1134266)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04873cam a2200349 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250413035105.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Nadir, Wydad |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Évaluation des pratiques de prescription des facteurs de croissance granulocytaires en oncologie au Maroc |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2025.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 5 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Granulocyte colony stimulating factor (G-CSF) plays a crucial role in reducing the risk of neutropoenia caused by chemotherapy, a frequent and severe complication of myelosuppression treatments. Consequently, the prophylactic use of G-CSF is of significant interest, as it allows treatment programmes to be respected and doses of chemotherapy to be maintained, while minimising the risk of febrile neutropoenia. However, as the prescription of G-CSF varies considerably among oncologists, this study aims to assess the different methods of prescribing G-CSF in daily practice among oncologists in Morocco. It seeks to understand how these professionals use these drugs, the protocols and directives which influence their choices, and to identify the obstacles which may limit their prescription. More than 80 oncologists took part in our study by responding to a questionnaire on the demographic data, knowledge of supportive care and the guidelines which they follow in their practice, prescription methods such as the choice of G-CSF, the dose, the length of treatment, and the secondary effects encountered in practice. This study also made it possible to identify obstacles to prescribing. Although 70% of participants were familiar with the prescription recommendations and followed guidelines from learned societies, mostly the ESMO (European Society of Medical Oncology), we identified a considerable lack of prescription as part of intermediate-risk febrile neutropoenia protocols (a risk of between 10% and 20%), which may be due to limited access to drugs, the cost of treatment, or differences between the recommendations of learned societies in oncology. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Les facteurs de croissance granulocytaires (G-CSF) jouent un rôle crucial dans la réduction du risque de neutropénie induite par la chimiothérapie, complication fréquente et sévère des traitements myélosuppresseurs. Par conséquent, l’utilisation prophylactique des G-CSF est d’un intérêt majeur, car elle permet de respecter les schémas thérapeutiques et de maintenir l’intensité des doses de chimiothérapie tout en minimisant le risque de neutropénie fébrile. Toutefois, comme la pratique de leur prescription varie considérablement parmi les oncologues, cette étude a pour objectif d’évaluer les différentes méthodes de prescription des G-CSF dans la pratique quotidienne des oncologues au Maroc. Elle cherche à comprendre comment ces professionnels utilisent ces médicaments, quels protocoles et directives influencent leurs choix, et à identifier les obstacles qui peuvent limiter leur prescription. Plus de 80 oncologues ont participé à notre étude en répondant au questionnaire portant sur les données démographiques, les connaissances en soin de support et les lignes directives suivies dans leurs pratiques, les modalités de prescription tels que le choix de la molécule de G-CSF, la dose, la durée de traitement, et les effets secondaires rencontrés en pratique. Cette étude a aussi permis de reconnaître les obstacles de prescription. Bien que 70 % des participants connaissent les recommandations des prescriptions et suivent les lignes directives par les sociétés savantes en majorité de l’European Society of Medical Oncology (ESMO), nous avons identifié une insuffisance considérable de prescriptions dans le cadre des protocoles à risque intermédiaire de neutropénie fébrile (soit un risque de 10 à 20 %), ce qui peut être dû à l’accès limité aux médicaments, au coût du traitement, ou encore à des divergences dans les recommandations des sociétés savantes en oncologie. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | facteurs de croissance granulocytaire |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | neutropénie |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | pratique des oncologues au Maroc |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | soins oncologiques de support |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | granulocyte colony-stimulating factor |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | neutropoenia |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | oncological supportive care |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | oncology practice in Morocco |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lkhoyaali, Sihame |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hachlaf, Mariem |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Abdi, Chaimae |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ghissassi, Brahim El |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mrabti, Hind |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Boutayeb, Saber |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Errihani, Hassan |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Innovations & Thérapeutiques en Oncologie | Volume 11 | 2 | 2025-04-11 | p. 95-99 | 2431-3203 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-innovations-et-therapeutiques-en-oncologie-2025-2-page-95?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-innovations-et-therapeutiques-en-oncologie-2025-2-page-95?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux